NV3P.F NANOVIRICIDES NEW DL-01

Healthcare Biotechnology Frankfurt Exchange
1.15 EUR
Close of Nov 12, 2026
0.6400 1.62
Market cap
EUR 29.4M
P/E
-
P/B
4.01x
ROE
-94.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is NV3P.F undervalued?

Graham number

The Graham number of NANOVIRICIDES NEW DL-01 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NANOVIRICIDES NEW DL-01 fundamental analysis

No fundamental analysis for NANOVIRICIDES NEW DL-01 yet.

NANOVIRICIDES NEW DL-01 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NANOVIRICIDES NEW DL-01

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup a…

Full company profile